Please assess the completion status of the following clinical trial:

Trial Title: Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of major depressive disorder consistent with DSM-IV-TR~* current episode greater than 8 weeks in duration~* Hamilton Depression score \>/- 21~* less than 25% reduction in depression during current episode assessed by ATRQ~Exclusion Criteria:~* Axis diagnosis of other psychiatric disorders~* Experiencing hallucinations, delusions, other psychotic symptomatology~* ECT during current episode

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): IV placebo
- GLYX-13, 1 mg/kg (Type: EXPERIMENTAL): None
- GLYX-13, 5 mg/kg (Type: EXPERIMENTAL): None
- GLYX-13, 10 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).